Chinese biotechnology company 3SBio has agreed to delist from the NASDAQ stock exchange after shareholders voted in favor of a take-private deal proposed by Chinese private equity firm CITIC Private Equity and the company’s CEO. The two parties, who own a combined 18 percent of 3SBio’s outstanding share capital, have agreed to buy the remaining shares at US$16.70 per share, valuing 3SBio at around US$370 million. The transaction will be financed through a combination of debt, equity and cash. CPE China Fund, the US$990 million private equity fund managed by CITIC Private Equity, will provide the equity portion.